Table 3.

Cox regression analysis with relapse after initial response [i.e. a ≥50% reduction in seizure frequency] (a) and stiripentol discontinuation or addition of another ASM (b) as outcome variables

Variables				Hazard ratio (CI 95%)		P value
(a) Relapse after a ≥50% reduction in seizure frequency
Age		Adult		1.0
		Paediatric		3.6 (1.2–11.2)		0.024
Epilepsy duration, months		≤ 60		1.0
		> 60		1.5 (0.8–2.8)		0.259
Aetiology		Genetic (DS)		1.0
		Other genetic		3.9 (1.4–10.6)		0.009
		Unknown		2.7 (1.1–6.7)		0.035
		Other		4.5 (1.6–12.6)		0.005
Epilepsy type		Combined		1.0
		Focal		0.4 (0.1–1.0)		0.045
		Generalised		0.6 (0.3–1.4)		0.248
Concomitant ASMs		CLB		3.7 (0.9–16.4)		0.080
		VPA		0.8 (0.4–1.6)		0.469
(b) Stiripentol discontinuation or addition of another ASM
Age	Adult		1.0
	Paediatric		1.6 (0.8–3.3)		0.184
Epilepsy duration, months	≤ 60		1.0
	> 60		0.98 (0.6–1.5)		0.929
Aetiology	Genetic (DS)		1.0
	Other genetic		2.8 (1.4–5.6)		0.003
	Unknown		2.40 (1.1–3.8)		0.032
	Other		3.0 (1.5–6.0)		0.001
Epilepsy type	Combined		1.0
	Focal		0.8 (0.5–1.2)		0.273
	Generalised		0.6 (0.4–1)		0.037
Concomitant ASMs	CLB		0.8 (0.4–1.6)		0.467
	VPA		0.7 (0.45–1.1)		0.467

ASMs antiseizure medications, CI confidence interval, CLB clobazam, DS Dravet syndrome, VPA sodium valproate